New drug combo aims to fight advanced esophageal cancer
NCT ID NCT07290010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy can help people with advanced esophageal cancer that has come back or spread. About 25 adults will receive the treatment for up to 24 months. The goal is to see if the combination shrinks tumors and controls the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hebei Medical University Fourth Hospital
RECRUITINGShijiazhuang, Hebei, 050000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return